source
- Ratio Therapeutics secures $70M Series C for radiopharma trials as Vogenx eyes $67M IPORatio Therapeutics, a Boston-based biotech, announced a $70 million Series C financing to fund its radiopharmaceutical development program. The round was led by existing backers Duquesne Family Of…
- Karyopharm stock tumbles after Phase 3 Xpovio trial fails in endometrial cancerKaryopharm announced that its Phase 3 XPORT-EC-042 study of Xpovio in endometrial cancer did not meet its primary endpoint. The failure represents the company's second unsuccessful attempt to expa…